Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
1 Nederlandse hepatologie in historisch en toekomstig perspectief hoofdstuk lezen eerste hoofdstuk lezen

2009 | OriginalPaper | Hoofdstuk

14 Metabole leverziekten

Auteurs : Prof.dr. H.J. Verkade, Dr. F.A.J.A. Bodewes, Dr. R. Houwen, Dr. R.A. de Vries, Dr. B. van Hoek, G. Visser

Gepubliceerd in: Leverziekten

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

In dit hoofdstuk worden enkele metabole leverziekten behandeld. Alfa-1-antitrypsinedeficiëntie is een erfelijke aandoening die geassocieerd is met long- en leverziekte. Cystic fibrosis is geassocieerd met leverziekte, waaronder cirrose en portale hypertensie. De ziekte van Wilson, eveneens een erfelijke aandoening, is een stoornis in het kopermetabolisme met gevolgen voor de lever.
vorige hoofdstuk 13 Alcoholische leverziekte
volgende hoofdstuk 15 Medicamenteus-toxisch leverlijden
Literatuur
1.
Fairbanks KD, Tavill AS. Liver disease in alpha-1-antitrypsin deficiency: a review. Am J Gastroenterol 2008; 103:2136–2141.PubMedCrossRef
2.
3.
Perlmutter DH, Brodsky JL, Balistreri WF, Trapnell BC. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review. Hepatology 2007;45:1313–1323.PubMedCrossRef
4.
Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver-cancer in alpha-1-antitrypsin deficiency. N Eng J Med 1986;314:736–739.CrossRef
5.
Fischer HP, Ortiz-Pallardo ME, Ko Y, Esch C, Zhou H. Chronic liver disease in heterozygous alpha-1-antitrypsin deficiency PiZ. J Hepatol 2000;33:883–892.PubMedCrossRef
6.
Sveger T. Liver-disease in alpha-1-antitrypsin deficiency detected by screening of 200,000 infants. N Eng J Med 1976;294:1316–1321.CrossRef
7.
Richtlijn Diagnostiek en Behandeling Cystic Fibrosis. Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2007.
8.
9.
Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database of Systematic Reviews 1999;3: CD000222. DOI: 10.1002/14651858.
10.
11.
12.
Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003;23:139–142.PubMedCrossRef
13.
14.
Bhutani VK, Maisels MJ, Stark AR, Buonocore G. Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants >or=35 weeks gestation. Neonatology 2008;94:63–67.PubMedCrossRef
15.
Colletti JE, Kothari S, Jackson DM, Kilgore KP, Barringer K. An emergency medicine approach to neonatal hyperbilirubinemia. Emerg Med Clin North Am 2007;25:1117–1135, vii.
16.
17.
Wennberg RP, Ahlfors CE, Bhutani VK, Johnson LH, Shapiro SM. Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns. Pediatrics 2006;117:474–485.PubMedCrossRef
18.
19.
Bosma PJ, Chowdhury JR, Bakker C, Gantla S, Deboer A, Oostra BA, Lindhout D, Tytgat GNJ, Jansen PLM, Oude Elferink RPJ, Chowdhury NR. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 1995;333:1171–1175.PubMedCrossRef
20.
Robertson KJ, Clarke D, Sutherland L, Wooster R, Coughtrie MW, Burchell B. Investigation of the molecular basis of the genetic deficiency of UDP-glucuronosyltransferase in Crigler-Najjar syndrome. J Inherit Metab Dis 1991;14:563–579.PubMedCrossRef
21.
Thayyil S, Milligan DW. Single versus double volume exchange transfusion in jaundiced newborn infants. Cochrane Database Syst Rev 2006;CD004592.
22.
23.
Oude Elferink RP, Paulusma CC, Groen AK. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 2006; 130:908–925.PubMedCrossRef
24.
Kubitz R, Keitel V, Haussinger D. Inborn errors of biliary canalicular transport systems. Methods Enzymol 2005;400:558–569.PubMedCrossRef
25.
Wagner M, Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. Ann Hepatol 2005;4:77–99.PubMed
26.
27.
Senyuz OF, Yesildag E, Kuruoglu S, Yeker Y, Emir H. Caroli’s disease in children: is it commonly misdiagnosed? Acta Paediatr 2005;94:117–120.PubMedCrossRef
28.
Arroyo M, Crawford JM. Hepatitic inherited metabolic disorders. Semin Diagn Pathol 2006;23:182–189.PubMedCrossRef
29.
Pietrangelo A. Hereditary Hemochromatosis – A new look at an old disease. N Engl J Med 2004;350:2383–2397.PubMedCrossRef
30.
Beutler E. Iron storage disease: facts, fiction and progress. Blood Cells, Molecules & Diseases 39;2007:140–147.CrossRef
31.
Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006;166:294–301.PubMedCrossRef
32.
Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221–230.PubMedCrossRef
33.
34.
Swinkels DW, Janssen MCH, Bergmans J, Marx JJM. Hereditary hemochromatosis: Genetic complexity and new diagnostic approaches. Clinical Chemistry 2006; 52(6):950–968.PubMedCrossRef
35.
Bergmans JPH, Kemna EHJM, Janssen MCH, Jacobs EMG, Stalenhoef AFH, Marx JJM, Swinkels DW. Hereditaire hemochromatose: nieuwe genen, nieuwe ziekten en hepcidine. Ned Tijdschr Geneesk 2007;151: 1121–1127.
36.
Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107–1119.PubMedCrossRef
37.
> Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008;111(7):3373–6. (Epub 2007, Nov 19.)
38.
Pietrangelo A. Non-invasive assessment of hepatic iron overload: are we finally there? J Hepatol 2005;42:153–154.PubMedCrossRef
39.
Pietrangelo A, Corradini E, Ferrara F, Vegetti A, De Jong G, Luca Abbati G, Paolo Arcuri P, Martinelli S, Cerofolini E. Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. Blood Cells Mol Dis 2006;37:192–196.PubMedCrossRef
40.
Swinkels DW, Jorna ATM, Raymakers RAP. Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of Hereditary Hemochromatosis. Neth J Med 2007;65:452–455.PubMed
41.
42.
Jacobs EMG, Hendriks JCM, Marx JJM, Deursen CThBM van, Kreeftenberg HG, Vries RA de, Stalenhoef AFH, Verbeek ALM, Swinkels DW. First-degree relatives of C282Y homozygous probands with clinically detected hemochromatosis have increased morbidity compared to the general population. The HEmochromatosis FAmily Study (HEFAS). Neth J Med 2007; 2007;65:425–433.PubMed
43.
Poblete-Gutierrez P, Wiederholt T, Merk HF, Frank J. The porphyrias: clinical presentation, diagnosis and treatment. Eur J Dermatol 2006;16:230–240.PubMed
44.
45.
Wijk HJ van, Baart de la FH, Berg JW Van Den, Edixhoven-Bosdijk A, Wilson JH. Blood exchange and transfusion therapy for acute cholestasis in protoporphyria. Dig Dis Sci 1988;33:1621–1625.PubMedCrossRef
46.
Bloomer JR. The porphyriasis. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff’s Diseases of the Liver. pp. 1231–60. 9th edn. Philadelphia: Lippincott Williams & Wilkins, 2003.
47.
Chemmanur AT, Bonkovsky HL. Hepatic porphyrias: diagnosis and management. Clin Liver Dis 2004;8:807–38, viii.PubMedCrossRef
48.
Wilson JH, Rooy FW de, te VK. Acute intermittent porphyria in The Netherlands. Heterogeneity of the enzyme porphobilinogen deaminase. Neth J Med 1986; 29:393–399.PubMed
49.
Wiederholt T, Poblete-Gutierrez P, Gardlo K, Goerz G, Bolsen K, Merk HF, Frank J. Identification of mutations in the uroporphyrinogen III cosynthase gene in German patients with congenital erythropoietic porphyria. Physiol Res 2006;55(Suppl 2):S85–S92.PubMed
50.
51.
Phillips JD, Whitby FG, Stadtmueller BM, Edwards CQ, Hill CP, Kushner JP. Two novel uroporphyrinogen decarboxylase (URO-D) mutations causing hepatoerythropoietic porphyria (HEP). Transl Res 2007;149: 85–91.PubMedCrossRef
52.
Meerman L. Erythropoietic protoporphyria. An overview with emphasis on the liver. Scand J Gastroenterol Suppl 2000:79–85.
53.
Gross U, Hoffmann GF, Doss MO. Erythropoietic and hepatic porphyrias. J Inherit Metab Dis 2000;23:641–661.PubMedCrossRef
54.
Gisbert JP, Garcia-Buey L, Alonso A, Rubio S, Hernandez A, Pajares JM, Garcia-Diez A, Moreno-Otero R. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur J Gastroenterol Hepatol 2004;16:689–692.PubMedCrossRef
55.
Siersema PD, Kate FJ ten, Mulder PG, Wilson JH. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 1992;12:56–61.PubMedCrossRef
56.
Thunnissen PL, Meyer J, Koning RW de. Acute intermittent porphyria and primary liver-cell carcinoma. Neth J Med 1991;38:171–174.PubMed
57.
Cassiman D, Vannoote J, Roelandts R, Libbrecht L, Roskams T, Van Den OJ, Fevery J, Garmyn M, Nevens F. Porphyria cutanea tarda and liver disease. A retrospective analysis of 17 cases from a single centre and review of the literature. Acta Gastroenterol Belg 2008; 71:237–242.PubMed
58.
Beukeveld GJ, Wolthers BG. Laboratoriumdiagnostiek bij porfyrieën: stoornissen in de heemsynthese, pp. 3–14. 22e dr., 1997.
59.
Beukeveld GJ, Bijleveld CM, Kuipers F, Kreeftenberg HG, Huizenga JR, Te VK, Wolthers BG. Evaluation and clinical application of the Enterotest for the determination of human biliary porphyrin composition. Eur J Clin Chem Clin Biochem 1995;33:453–462.PubMed
60.
Beukeveld GJ, Meerman L, Huizenga JR, Venekamp-Hoolsema EE, Gips CH, Wolthers BG. Determination of porphyrins in bile using high performance liquid chromatography and some clinical applications. Eur J Clin Chem Clin Biochem 1994;32:153–159.PubMed
61.
Parker M, Corrigall AV, Hift RJ, Meissner PN. Molecular characterization of erythropoietic protoporphyria in South Africa. Br J Dermatol 2008;159:182–191.PubMedCrossRef
62.
Bloomer J, Wang Y, Singhal A, Risheg H. Molecular studies of liver disease in erythropoietic protoporphyria. J Clin Gastroenterol 2005;39:S167–S175.PubMedCrossRef
63.
Lambrecht RW, Thapar M, Bonkovsky HL. Genetic aspects of porphyria cutanea tarda. Semin Liver Dis 2007;27:99–108.PubMedCrossRef
64.
Thunell S, Pomp E, Brun A. Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br J Clin Pharmacol 2007;64:668–679.PubMedCentralPubMedCrossRef
65.
Kuo HC, Lee MJ, Chuang WL, Huang CC. Acute intermittent porphyria with peripheral neuropathy: a follow-up study after hematin treatment. J Neurol Sci 2007;260:231–235.PubMedCrossRef
66.
Sardh E, Rejkjaer L, Andersson DE, Harper P. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet 2007;46:335–349.PubMedCrossRef
67.
De Verneuil H, Robert-Richard E, Ged C, Mazurier F, Richard E, Moreau-Gaudry F. Successful gene therapy of mice with congenital erythropoietic porphyria . Med Sci (Paris) 2008;24:615–620.CrossRef
68.
Seth AK, Badminton MN, Mirza D, Russell S, Elias E. Liver transplantation for porphyria: who, when, and how? Liver Transpl 2007;13:1219–1227.PubMedCrossRef
69.
Soonawalla ZF, Orug T, Badminton MN, Elder GH, Rhodes JM, Bramhall SR, Elias E. Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004;363:705–706.PubMedCrossRef
70.
Stojeba N, Meyer C, Jeanpierre C, Perrot F, Hirth C, Pottecher T, Deybach JC. Recovery from a variegate porphyria by a liver transplantation. Liver Transpl 2004;10:935–938.PubMedCrossRef
71.
Do KD, Banner BF, Katz E, Szymanski IO, Bonkovsky HL. Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. Transplantation 2002;73:469–472.PubMedCrossRef
72.
McGuire BM, Bloomer JR. Use of extracorporeal albumin dialysis for erythropoietic protoporphyria. Liver Transpl 2007;13:639–640.PubMedCrossRef
73.
Eefsen M, Rasmussen A, Wulf HC, Brock A, Hansen BA. Erythropoietic protoporphyria and pretransplantation treatment with nonbiological liver assist devices. Liver Transpl 2007;13:655–657.PubMedCrossRef
74.
Wahlin S, Aschan J, Bjornstedt M, Broome U, Harper P. Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 2007;46:174–179.PubMedCrossRef
75.
Rand EB, Bunin N, Cochran W, Ruchelli E, Olthoff KM, Bloomer JR. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 2006;118:e1896–e1899.PubMedCrossRef
76.
McGuire BM, Bonkovsky HL, Carithers RL Jr., Chung RT, Goldstein LI, Lake JR, Lok AS, Potter CJ, Rand E, Voigt MD, Davis PR, Bloomer JR. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005;11:1590–1596.PubMedCrossRef
77.
Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment. Acta Derm Venereol 2007;87:401–405.PubMedCrossRef
78.
79.
Bertoli LF, Barton JC. Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer. Clin Breast Cancer 2007;7:716–718.PubMedCrossRef
80.
Roche M, Daly P, Crowley V, Darby C, Barnes L. A case of porphyria cutanea tarda resulting in digital amputation and improved by anastrazole. Clin Exp Dermatol 2007;32:327–328.PubMedCrossRef
81.
Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 2007;67(18):2697–2716.PubMedCrossRef
82.
Torbenson M, Chen YY, Brunt E, Cummings OW, Gottfried M, Jakate S, Liu YC, Yeh MM, Ferrell L. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol 2006;30(4):508–513.PubMedCrossRef
Metagegevens
Titel
14 Metabole leverziekten
Auteurs
Prof.dr. H.J. Verkade
Dr. F.A.J.A. Bodewes
Dr. R. Houwen
Dr. R.A. de Vries
Dr. B. van Hoek
G. Visser
Copyright
2009
Uitgeverij
Bohn Stafleu van Loghum
Boek
Leverziekten

Print ISBN: 978-90-313-7436-6

Elektronisch ISBN: 978-90-313-7437-3

Copyright: 2009

DOI
https://doi.org/10.1007/978-90-313-7437-3_14